Equities Analysts Offer Predictions for Synlogic Inc’s FY2019 Earnings (NASDAQ:SYBX)

Synlogic Inc (NASDAQ:SYBX) – Equities researchers at Piper Jaffray Companies increased their FY2019 EPS estimates for Synlogic in a report issued on Wednesday, November 13th. Piper Jaffray Companies analyst E. Tenthoff now forecasts that the biotechnology company will earn ($1.77) per share for the year, up from their prior estimate of ($1.89). Piper Jaffray Companies has a “Overweight” rating and a $7.00 price objective on the stock. Piper Jaffray Companies also issued estimates for Synlogic’s Q4 2019 earnings at ($0.42) EPS, Q1 2020 earnings at ($0.42) EPS, Q2 2020 earnings at ($0.46) EPS, Q3 2020 earnings at ($0.46) EPS, Q4 2020 earnings at ($0.50) EPS, FY2020 earnings at ($1.84) EPS, Q1 2021 earnings at ($0.51) EPS, Q2 2021 earnings at ($0.55) EPS, Q3 2021 earnings at ($0.55) EPS and FY2021 earnings at ($2.20) EPS.

SYBX has been the subject of several other reports. HC Wainwright reissued a “buy” rating and issued a $13.00 price objective on shares of Synlogic in a research report on Monday, September 9th. Chardan Capital reissued a “buy” rating on shares of Synlogic in a research report on Thursday, September 19th. ValuEngine raised Synlogic from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Oppenheimer cut Synlogic from an “outperform” rating to a “market perform” rating in a research report on Tuesday, August 20th. Finally, Wedbush reissued an “outperform” rating and issued a $20.00 price objective on shares of Synlogic in a research report on Friday, August 9th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $13.69.

SYBX opened at $2.10 on Friday. Synlogic has a 1-year low of $1.96 and a 1-year high of $11.43. The company has a current ratio of 14.43, a quick ratio of 14.43 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $70.42 million, a price-to-earnings ratio of -1.03 and a beta of 2.56. The business has a 50 day moving average of $2.18 and a 200-day moving average of $5.31.

Synlogic (NASDAQ:SYBX) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.09. Synlogic had a negative return on equity of 36.32% and a negative net margin of 4,574.82%. The company had revenue of $0.31 million during the quarter, compared to analysts’ expectations of $0.46 million.

A number of hedge funds have recently modified their holdings of SYBX. Flagship Harbor Advisors LLC bought a new position in Synlogic in the third quarter worth $34,000. Parametric Portfolio Associates LLC bought a new position in Synlogic in the second quarter worth $195,000. Charles Schwab Investment Management Inc. lifted its position in Synlogic by 11.1% in the second quarter. Charles Schwab Investment Management Inc. now owns 37,208 shares of the biotechnology company’s stock worth $339,000 after purchasing an additional 3,708 shares during the period. Northern Trust Corp lifted its position in Synlogic by 17.1% in the second quarter. Northern Trust Corp now owns 201,613 shares of the biotechnology company’s stock worth $1,835,000 after purchasing an additional 29,401 shares during the period. Finally, Vanguard Group Inc. lifted its position in Synlogic by 0.3% in the second quarter. Vanguard Group Inc. now owns 770,641 shares of the biotechnology company’s stock worth $7,013,000 after purchasing an additional 2,558 shares during the period. 64.98% of the stock is owned by hedge funds and other institutional investors.

Synlogic Company Profile

Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.

See Also: Cash Asset Ratio

Earnings History and Estimates for Synlogic (NASDAQ:SYBX)

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.